Dong-A announced on 24 July that its sales for the second quarter of 2009 has recorded 203,9 billion won, up 17.0% compared with same period of 2008(174.2 billion won.
Its operating profit (21.5 billion won) and net profit(14.6 billion won) also have increased 4.1% and 38.5%, respectively.
Dong-A explained that the sales of its profitable business sections have increased thanks to the even growth in the ETC business and the OTC business.
And its own developed drugs such as 'STILLRN(Anti Peptic ulcer drug)', 'ZYDENA(Erectile dysfunction treatment drug (PDE5 inhibitor)' and 'PLAVIOR(Anti Arteriosclerosis drug)' have shown high growth rate.
The sales of the drugs have increased 40 % compared with same period of last year, thanks to their export growth in preexisted overseas markets(South America and South Asia etc.) and the sale of 'ZYDENA' in Russia.
President of Dong-A Pharmaceutical, Kim won-bae said, "These results could lead up to strengthen the pipeline of new drugs and develop new drugs with high market competitiveness. <헬스코리아뉴스>
저작권자 © 헬스코리아뉴스 무단전재 및 재배포 금지
